Development of Dopamine D1 Receptor Agonists for PET Imaging

用于 PET 成像的多巴胺 D1 受体激动剂的开发

• 批准号: 8263752
• 负责人: Balasubramaniam Easwaramoorthy
• 金额: $ 23.99万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-10 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8263752
• 关键词: Affinity; Agonist; Alcohol dependence; Animals; Area; Attention deficit hyperactivity disorder; Benzazepines; Binding; Binding Sites; Biodistribution; Biological Assay; Blood - brain barrier anatomy; Brain; Characteristics; Chemical Structure; Chemistry; Clinical Research; Cognitive; Computer Simulation; Concentration measurement; Corpus striatum structure; Cyclic AMP; Cyclotrons; DRD2 gene; Detection; Development; Disease; Dopamine; Dopamine D1 Receptor; Dopamine Receptor; Dose; Drug Addiction; Effectiveness; Evaluation; Fluorides; Functional disorder; Future; G-Protein-Coupled Receptors; Goals; HTR2A gene; High Pressure Liquid Chromatography; Human; Image; Image Analysis; In Vitro; Investigation; Label; Lead; Ligands; Locomotion; Mass Spectrum Analysis; Methods; Modification; National Institute of Mental Health; Neuraxis; Normal saline; Nucleus Accumbens; Parkinson Disease; Performance; Permeability; Plasma; Play; Positron-Emission Tomography; Preclinical Drug Evaluation; Primates; Procedures; Property; Prosencephalon; Radioactive; Radioactivity; Radiolabeled; Rattus; Reagent; Research; Research Project Grants; Resolution; Rodent; Role; Scheme; Schizophrenia; Screening procedure; Skeleton; Specificity; Spiperone; Structure-Activity Relationship; Substantia nigra structure; Testing; Thalamic structure; Therapeutic; Tracer; base; caudate nucleus; cognitive enhancement; design; drug development; frontal lobe; in vivo; interest; neuropsychiatry; neurotransmission; nonhuman primate; novel; nucleophilic substitution; olfactory bulb; pharmacophore; pre-clinical; programs; public health relevance; putamen; radioligand; radiotracer; receptor; therapeutic target; three dimensional structure; tool; uptake

DESCRIPTION (provided by applicant): The Dopamine D1 receptor (D1R) plays an important role in the pathophysiology of neuropsychiatric diseases such as schizophrenia and Parkinson's disease and is an important target for cognitive enhancement strategies. The currently available D1R radioligands, [11C]NNC112 and [11C]SCH23390, are antagonists. It is our goal to synthesize a selective, full D1R agonist utilizing known chemical structures, modifying them to introduce pendent groups for radiolabeling, resulting in the synthesis of D1R-PET-ligands, and to assess them in rodents and non-human primates for suitability as D1R imaging agents. Dihydrexidine and doxanthrine are potent, highly selective and fully efficacious D1R agonists. In addition, many ligand-based computational modeling approaches, such as pharmacophore detection and interaction of ligands at the binding sites of the D1R, have been used and highlight the effectiveness of designing D1R agonists using the -phenyldopamine pharmacophore template. In this regard, we propose to synthesize four 18F labeled PET ligands for imaging D1R in vivo. The in vitro binding affinities of these agents will be determined and used to characterize the potency and selectivity of the new compounds. A high purity, high yield radiolabeling procedure will be developed using 18F-fluoride from a cyclotron and respective precursors. Dynamic PET studies with the 18F- D1R-PET-ligands will be performed in rats using a microPET scanner. The D1R agonist binding characteristics of the radiotracers will be calculated in animals that are vehicle-treated or pre-blocked with receptor-saturating doses of SCH23390. Non-human primate PET studies will be carried out with the 18F- D1R-PET-ligands that demonstrate sufficient potential in the rat studies. Ligands that are shown to have appropriate properties in these preclinical rodent and primate PET studies will be candidates for future examination as tracers in human clinical studies, with further support to continue the project sought through the R01 mechanism. PUBLIC HEALTH RELEVANCE: The dopamine D1 receptor (D1R) is the most abundant dopamine receptor in the central nervous system. Specifically, the D1R has been implicated in a variety of neuropsychiatric disorders such as schizophrenia and Parkinson's disease, and is a target for therapeutics and drug development. In this project, we propose to develop D1R agonist PET ligands to allow in vivo investigation of the functional state of the receptor.

描述(申请人提供)：多巴胺D1受体(D1R)在精神分裂症和帕金森病等神经精神疾病的病理生理学中发挥重要作用，是认知增强策略的重要目标。目前可用的D1R放射性配体[11C]NNC112和[11C]SCH23390是拮抗剂。我们的目标是利用已知的化学结构合成一种选择性的、完整的D1R激动剂，对其进行修饰以引入用于放射性标记的侧基，从而合成D1R-PET-配体，并评估它们作为D1R显像剂在啮齿动物和非人类灵长类动物中的适用性。二氢呋喃西定和多西沙林是一种高效、高选择性、完全有效的D1R激动剂。此外，许多基于配体的计算建模方法，如药效团检测和D1R结合位点上配体的相互作用，已经被使用，并突出了使用-苯基多巴胺药效团模板设计D1R激动剂的有效性。在这方面，我们建议合成四个18F标记的PET配体，用于体内D1R的成像。这些试剂的体外结合亲和力将被测定并用于表征新化合物的效力和选择性。使用回旋加速器的18F-氟化物和各自的前体，将开发一种高纯度、高产率的放射性标记程序。18F-D1R-PET-配体的动态PET研究将使用微型PET扫描仪在大鼠身上进行。放射性示踪剂的D1R激动剂结合特性将在接受载体治疗或用受体饱和剂量SCH23390预先阻断的动物中计算。非人灵长类PET研究将使用18F-D1R-PET配体进行，这些配体在大鼠研究中显示出足够的潜力。在这些临床前啮齿动物和灵长类PET研究中被证明具有适当性质的配体将成为未来在人类临床研究中作为示踪剂的候选对象，并将进一步支持通过R01机制寻求的项目的继续。 与公共健康相关：多巴胺D1受体(D1R)是中枢神经系统中最丰富的多巴胺受体。具体地说，D1R与精神分裂症和帕金森氏症等多种神经精神障碍有关，是治疗和药物开发的靶点。在这个项目中，我们建议开发D1R激动剂PET配体，以便在体内研究受体的功能状态。